"Based on the available data, and its benefit-risk assessment, FDA has removed the recommended pause in the use of Ixchiq in ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

Valneva SE ( NASDAQ: VALN) said on Thursday that the FDA has lifted its pause on the use of its chikungunya vaccine, Ixchiq, ...

While anti-vaxxers are thrilled, experts warn that defunding mRNA development takes away our already-proven best weapon ...

The FDA has removed a pause in the use of Valneva’s chikungunya vaccine in older adults while tweaking the shot’s label with stricter language.

Ixchiq now has a warning about its use among elderly people with multiple underlying health conditions after postmarketing ...

A separate Danish study showed that the two mRNA vaccines were also safe, with no increase in adverse events of special ...

Kennedy said Tuesday that the terminated contracts were worth nearly $500 million. Among them is an award to the University ...

DIRECTING A CHANGING CDC — The Senate voted to confirm Susan Monarez as the next CDC director Tuesday, marking an end to the ...

The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure.